Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06367465 · ClinicalTrials.gov registry record
Feasibility and Acceptability of HCV Treatment in Pregnancy
A clinical trial of Hepatitis C and Pregnancy Complications, sponsored by Washington University School of Medicine.
- Recruiting
- Registry status
- 50
- Enrollment target
- 2
- Study locations
NCT06367465: Recruiting study of Hepatitis C and Pregnancy Complications, sponsored by Washington University School of Medicine.
NCT06367465 is a study of Hepatitis C and Pregnancy Complications that is actively recruiting participants, run by Washington University School of Medicine. The registered enrollment target is 50 participants, below the 1,890-participant average among 106 other Hepatitis C trials with a reported enrollment target (97% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06367465, a study of Hepatitis C and Pregnancy Complications, is actively recruiting participants, sponsored by Washington University School of Medicine.
- RECRUITING
- Registry status
- 50 participants
- Enrollment target
- 2
- Study locations
Study Summary
Pregnant adults over the age of 18 who are seen in the Washington University obstetrics and gynecology, maternal fetal medicine or infectious diseases clinic or admitted to BJH with hepatitis C virus infection who have a history of past or current drug use Participant Duration: Approximately 1 year. Aims: Aim 1 - Evaluate adherence and treatment completion rates when glecaprevir-pibrentasvir is started during pregnancy for women who use drugs. Aim 2 - Evaluate patient experience with hepatitis C virus treatment during pregnancy.
Primary Outcome
The primary objective of this study is to assess patient adherence and treatment completion rates of women with a history of past or current drug use who receive initiation of Hepatitis C Virus treatment with glecaprevir-pibrentasvir during pregnancy. The primary objective of this study is to assess patient adherence and treatment completion rates of women with a history of past or current drug use who receive initiation of Hepatitis C Virus treatment with glecaprevir-pibrentasvir during pregnan
Conditions Studied
Interventions
- DRUG Glecaprevir-pibrentasvir
Study Locations (2)
Missouri
- Barnes Jewish Hospital - St Louis
- Washington Univeristy - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2024-02-01 |
| Est. Completion | 2026-02-28 |
What NCT06367465 shows while recruiting
NCT06367465 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 1,890-participant average among 106 other Hepatitis C trials with a reported enrollment target (97% lower).
The record links to 2 conditions, with Hepatitis C appearing as the primary indexed condition, and to 1 intervention - of which Glecaprevir-pibrentasvir is the first listed.
NCT06367465 reports a single indexed study location in Missouri.
Frequently Asked Questions
What is clinical trial NCT06367465 about?
NCT06367465 is a clinical study titled "Feasibility and Acceptability of HCV Treatment in Pregnancy". Pregnant adults over the age of 18 who are seen in the Washington University obstetrics and gynecology, maternal fetal medicine or infectious diseases clinic or admitted to BJH with hepatitis C virus infection who have a history of past or current drug use Participant Duration: Approximately 1 year...
What is the current status of trial NCT06367465?
This trial is currently recruiting. The enrollment target is 50 participants. The study started on 2024-02-01. Estimated completion is 2026-02-28.
What conditions does trial NCT06367465 study?
This clinical trial studies the following conditions: Hepatitis C, Pregnancy Complications.
What interventions are being tested in trial NCT06367465?
The interventions under investigation include: Glecaprevir-pibrentasvir (DRUG).
Who is sponsoring clinical trial NCT06367465?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06367465 being conducted?
This trial has 2 study locations across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatitis C
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06367465's enrollment target sits among peer trials
50 73rd of 106 higher than 33 of 106 other Hepatitis C trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hepatitis C trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
DBS TaT in Peer-assisted Telemedicine for Hepatitis C
RECRUITING · NA
-
Evaluation of Patients With Liver Disease
RECRUITING
-
The HOPE Study: Characterizing Patients With Hepatitis B and C
RECRUITING
-
Project I Test: Implementing HIV Testing in Opioid Treatment Programs
RECRUITING · NA
-
Partner Navigation Intervention for Hepatitis C Treatment Among Young People Who Inject Drugs
RECRUITING · NA
-
The Treatment in Pregnancy for Hepatitis C ("TiP-HepC") Registry
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI